Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312

version: 26; Last updated: 2025-08-18 13:22:42+0000

Profile: NonComparativeEvidence

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/367928

identifier: FEvIR Object Identifier/367928, FEvIR Linking Identifier/NCT03640312-otherOutcomeMeasure-0--OG001

name: NCT03640312_otherOutcomeMeasure_0_OG001

title: Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312

citeAs:

Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Candesartan

note: ,

Outcome Measure Population Description: All randomized participants

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)

variableDefinition

variableRole: Outcome

observed: Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks - (NCT03640312)

statistic

statisticType: Count of Participants

quantity: 0 Participants

SampleSizes

-KnownDataCount
*30

AttributeEstimates

-TypeQuantity
*Percentage0 %